Cohance Lifesciences Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
COHANCE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 5.3 pts less than Nifty Smallcap 250 and 5.0 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Cohance Lifesciences reported a significant decline in FY26 performance. Standalone revenue fell to ₹2,030.50 Crores from ₹2,504.43 Crores in the prior year (restated), while net profit dropped to ₹228.71 Crores from ₹491.18 Crores. Consolidated revenue was ₹2,268.55 Crores versus ₹2,608.50 Crores, with net profit at ₹150.12 Crores versus ₹484.24 Crores. The company completed a merger with erstwhile Cohance Lifesciences Limited effective May 1, 2025, and prior period figures have been restated to reflect this amalgamation. Exceptional items of ₹29.47 Crores included a ₹16.51 Crores customer settlement claim, ₹4.86 Crores impact from new labour codes, and ₹8.10 Crores restructuring expenses. Auditors issued an unmodified opinion, and the Board also approved updates to Key Managerial Personnel policy.
The sharp decline in revenue and profit, combined with exceptional items including a customer settlement, signals operational challenges. Despite positive operating cash flows, shareholders should note the significant year-over-year deterioration and the impact of merger-related restructuring costs.